INT41 Gene Therapy for Neurodegenerative Diseases Granted Priority Patent Status
News
The patent application for gene therapy candidate INT41, developed by Vybion for the treatment of Huntington’s disease, spinal muscular atrophy (SMA), and other neurodegenerative diseases, was granted Track One status from ... Read more